Dermapharm Shares Fall After German Regulator Announces Accounting Probe
Germany's financial regulator, BaFin, has publicly announced a formal investigation into potential accounting irregularities at Dermapharm, prompting a significant drop in the company's share price on Friday.
Shares of the German pharmaceutical company Dermapharm experienced a sharp decline on Friday, July 17, after the nation's financial supervisory authority, BaFin, announced it had opened a formal probe into the company's 2025 financial statements. [1, 3] The stock tumbled by as much as 9% in early trading, marking its most significant single-day drop in approximately nine years, before recovering some losses to close down around 2.5% to 3%. [1, 3, 5]
Focus on Accounting Irregularities
The regulator stated it has concrete evidence of potential accounting violations in Dermapharm's 2025 consolidated financial statements and management report. [1] The investigation, which was officially launched on July 14 but only made public on Friday, centers on two specific concerns. [1, 5]
The first issue involves a receivable of €63.2 million, including interest claims, that BaFin suspects may have been recorded incorrectly. [1, 3] The second area of focus is on transactions with a related party that the authority believes were inadequately explained in the company's financial disclosures. [1, 3] Dermapharm had not issued an immediate public response to the investigation. [1]
Market and Company Context
The negative news hit the market on a day when the broader German DAX index was already trading lower, weighed down by a global sell-off in technology stocks. [1, 5] Dermapharm's shares had seen a steeper decline in pre-market trading before the main session began. [1]
The probe into its 2025 accounting follows a year in which the company reported a 1.3% decline in revenue to €1.2 billion, though its adjusted operating profit grew by 2.9% to €324.8 million. [3] Earlier in 2026, the company had confirmed its financial guidance for the year. [4, 10]
Sources
- All News — Why is Dermapharm stock sliding today?
- Why is Dermapharm stock sliding today?
- Why is Dermapharm stock sliding today? By Investing.com
- BaFin reviews Dermapharm's financial statements for irregularities – MarketScreener
- Frankfurt Stocks at the Open: Tech weakness pulls the Dax slightly lower | MarketScreener
- Dermapharm Holding Se Confirms Earnings Guidance for 2026 | MarketScreener
- Dermapharm Holding SE performs in line with projections in Q1 2026 and confirms guidance – EQS News
Educational and informational content. Not financial, investment, tax or legal advice, nor a recommendation to buy or sell any asset.
